Comparable data were shown in head and neck squamous cell carcinoma with both, PD-L1 and PD-L2 positivity in tumor, stromal and immune cells significantly predicting clinical response to pembrolizumab (Yearley et al. 2017). Here, PDCD1LG2 is linked to neoplasm.